Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Objective: To investigate the long-term safety and tolerability of a once-daily, dual-release hydrocortisone (DR-HC) tablet as oral glucocorticoid replacement therapy in patients with primary adrenal insufficiency (AI). Design: Prospective, open-label, multicenter, 5-year extension study of DR-HC conducted at five university clinics in Sweden. Methods: Seventy-one adult patients diagnosed with primary AI who were receiving stable glucocorticoid replacement therapy were recruited. Safety and tolerability outcomes included adverse events (AEs), intercurrent illness episodes, laboratory parameters and vital signs. Quality of life (QoL) was evaluated using generic questionnaires. Results: Total DR-HC exposure was 328 patient-treatment years. Seventy patients reported 1060 AEs (323 per 100 patient-years); 85% were considered unrelated to DR-HC by the investigator. The most common AEs were nasopharyngitis (70%), fatigue (52%) and gastroenteritis (48%). Of 65 serious AEs reported by 32 patients (20 per 100 patient-years), four were considered to be possibly related to DR-HC: acute AI (n = 2), gastritis (n = 1) and syncope (n = 1). Two deaths were reported (fall from height and subarachnoid hemorrhage), both considered to be unrelated to DR-HC. From baseline to 5 years, intercurrent illness episodes remained relatively stable (mean 2.6–5.4 episodes per patient per year), fasting plasma glucose (0.7 mmol/L;P < 0.0001) and HDL cholesterol (0.2 mmol/L;P < 0.0001) increased and patient-/investigator-assessed tolerability improved. QoL total scores were unchanged but worsening physical functioning was recorded (P = 0.008). Conclusions: In the first prospective study evaluating the long-term safety of glucocorticoid replacement therapy in patients with primary AI, DR-HC was well tolerated with no safety concerns observed during 5-year treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse metabolic and cardiovascular consequences of circadian misalignment
Scheer, F. A. J. L., Hilton, M. F., Mantzoros, C. S., & Shea, S. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808180106 · Cited by 2,351
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769
Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus
Iglay, K., Hannachi, H., Joseph Howie, P., Xu, J., Li, X., Engel, S. S., Moore, L. M., & Rajpathak, S. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1168291 · Cited by 511
Premature Mortality in Patients with Addison’s Disease: A Population-Based Study
Bergthorsdottir, R., Leonsson-Zachrisson, M., Odén, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0076 · Cited by 490
Self-citationHahner, S., Spinnler, C., Fassnacht, M., Burger-Stritt, S., Lang, K., Milovanovic, D., Beuschlein, F., Willenberg, H. S., Quinkler, M., & Allolio, B. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3191 · Cited by 394
Hahner, S., Loeffler, M., Bleicken, B., Drechsler, C., Milovanovic, D., Fassnacht, M., Ventz, M., Quinkler, M., & Allolio, B. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0884 · Cited by 346
Johannsson, G., Nilsson, A. G., Bergthorsdottir, R., Burman, P., Dahlqvist, P., Ekman, B., Engström, B. E., Olsson, T., Ragnarsson, O., Ryberg, M., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1926 · Cited by 329 · cited 10×
“…randomized, controlled, two-way crossover, clinical trial conducted in patients with primary AI showed that DR-HC treatment was associated with significant improvements in cardiometabolic factors and QoL compared with conventional hydrocortisone tablets administered three times per day (TID) (22).”
InfluentialSelf-citationFilipsson, H., Monson, J. P., Koltowska-Häggström, M., Mattsson, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0524 · Cited by 321 · cited 2×
“The minimal changes in serum lipids with DR-HC are in contrast to standard glucocorticoid therapy at doses of ≥ 20 mg/day, which has been shown to be associated with an adverse cardiovascular risk profile (10).”
Self-citationGrossi, E., Groth, N., Mosconi, P., Cerutti, R., Pace, F., Compare, A., & Apolone, G. (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-88 · Cited by 291
Kumari, M., Badrick, E., Ferrie, J., Perski, A., Marmot, M., & Chandola, T. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0555 · Cited by 229 · cited 1×
“Glucocorticoid overexposure is associated with altered sleep and increased cardiometabolic risk, particularly when cortisol levels are elevated in the late afternoon and evening (1, 10, 11, 12, 13, 14, 15, 16).”
Cited by
Husebye, E. S., Pearce, S. H., Krone, N. P., & Kämpe, O. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00136-7 · Cited by 378
Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy
Hardy, R. S., Zhou, H., Seibel, M. J., & Cooper, M. S. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00097 · Cited by 258
Hahner, S., Ross, R. J., Arlt, W., Bancos, I., Burger-Stritt, S., Torpy, D. J., Husebye, E. S., & Quinkler, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00252-7 · Cited by 223
Central adrenal insufficiency in children and adolescents
Patti, G., Guzzeti, C., Di Iorgi, N., Maria Allegri, A. E., Napoli, F., Loche, S., & Maghnie, M. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.03.012 · Cited by 75
Adrenal crisis in infants and young children with adrenal insufficiency: Management and prevention
Bizzarri, C., Capalbo, D., Wasniewska, M. G., Baronio, F., Grandone, A., & Cappa, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1133376 · Cited by 13
Metadata
- Authors
- Nilsson, A. G., Bergthorsdottir, R., Burman, P., Dahlqvist, P., Ekman, B., Engström, B. E., Ragnarsson, O., Skrtic, S., Wahlberg, J., Achenbach, H., Uddin, S., Marelli, C., & Johannsson, G.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-06
- Volume
- 176
- Issue
- 6
- Pages
- 715-725
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2597155438
- Cited by
- 38
- References
- 19
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study. https://app.cochat.ai/papers/10.1530/eje-17-0067
- The paper
- Nilsson, A. G., Bergthorsdottir, R., Burman, P., Dahlqvist, P., Ekman, B., Engström, B. E., Ragnarsson, O., Skrtic, S., Wahlberg, J., Achenbach, H., Uddin, S., Marelli, C., & Johannsson, G. (2017). Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study. European Journal of Endocrinology. https://doi.org/10.1530/eje-17-0067
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.